Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DBET57 exerts anti-cancer effects in neuroblastoma

ABSTRACT: dBET57 exerts anti-cancer effects in neuroblastoma

PROVIDER: PRJNA858693 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR20203985_1.fastq.gz	Fastqsanger.gz
	SRR20203985_2.fastq.gz	Fastqsanger.gz
	SRR20203986_1.fastq.gz	Fastqsanger.gz
	SRR20203986_2.fastq.gz	Fastqsanger.gz
	SRR20203987_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

BRD4 inhibitor GNE987 exerts anti-cancer effects in Neuroblastoma

Project description:BRD4 inhibitor GNE987 exerts anti-cancer effects in Neuroblastoma

| PRJNA785569 | ENA

BRD4 inhibitor MZ1 exerts anti-cancer effects in Neuroblastoma

Project description:BRD4 inhibitor MZ1 exerts anti-cancer effects in Neuroblastoma

| PRJNA797669 | ENA

BRD4 inhibitor GNE987 exerts anti-cancer effects in Neuroblastoma (ChIP-Seq)

Project description:BRD4 inhibitor GNE987 exerts anti-cancer effects in Neuroblastoma (ChIP-Seq)

| PRJNA800647 | ENA

BRD4 inhibitor GNE987 exerts anti-cancer effects in Osteosarcoma

Project description:BRD4 inhibitor GNE987 exerts anti-cancer effects in Osteosarcoma

| PRJNA1019364 | ENA

The FAK-Inhibitor BI 853520 exerts anti-tumor effects in breast cancer

Project description:The FAK-Inhibitor BI 853520 exerts anti-tumor effects in breast cancer

| PRJNA477312 | ENA

dBET57 exerts anti-cancer effects in neuroblastoma

Project description:Neuroblastoma (NB) is the most common extracranial solid tumor of childhood, which is derived from primordial neural crest cells. dBET57, a new cereblon (CRBN) based inhibitor developed by PROTAC technology. It binds to the BET protein families BRD2, BRD3, and BRD4, which are recruited to the proteasome system for selective ubiquitination degradation. However, the function of dBET57 has not been assessed in NB models so far. In the present study, RNA-seq analysis was performed to explore the effect of dBET57 on NB cells.

2022-12-09 | GSE208184 | GEO

BRD4 inhibitor GNE987 exerts anti-cancer effects in Neuroblastoma

Project description:Neuroblastoma (NB) is the most common extracranial solid tumor of childhood, which is derived from primordial neural crest cells. GNE987 is a newly developed von Hippel-Lindau tumor suppressor (VHL)-based pan-BET-targeting PROTAC, which can bind to the target proteins (BET proteins, including BRD2, BRD3, and BRD4) and recruit them to the ubiquitin/ proteasome system for selective degradation. However, the function of GNE987 has not been assessed in NB models so far. In the present study, RNA-seq analysis was performed to explore the effect of GNE987 on NB cells.

2022-03-23 | GSE190002 | GEO

BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting C-Myc and S100A16 in Glioblastoma

Project description:BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting C-Myc and S100A16 in Glioblastoma

| PRJNA835712 | ENA

BRD4 inhibitor GNE987 exerts anti-cancer effects in Neuroblastoma (ChIP-Seq)

Project description:Neuroblastoma (NB) is the most common extracranial solid tumor of childhood, which is derived from primordial neural crest cells. GNE987 is a newly developed von Hippel-Lindau tumor suppressor (VHL)-based pan-BET-targeting PROTAC, which can bind to the target proteins (BET proteins, including BRD2, BRD3, and BRD4) and recruit them to the ubiquitin/ proteasome system for selective degradation. However, the function of GNE987 has not been assessed in NB models so far. In the present study, ChIP-Seq analysis was performed to explore the effect of GNE987 on NB cells.

2022-03-23 | GSE194430 | GEO

Systemically administered extremely low HMGN1 with anti-CD4 depleting antibody exerts synergistic anti-tumor effects

Project description:Systemically administered extremely low HMGN1 with anti-CD4 depleting antibody exerts synergistic anti-tumor effects

| PRJNA450754 | ENA